Published in Health Business Week, December 22nd, 2006
It is widely recognized that new methods of treating and diagnosing Alzheimer disease are urgently needed in the face of an impending world-wide epidemic of Alzheimer disease. Currently, an estimated 4.5 million Americans and more than 15 million people around the world suffer from the disease. By 2050, this number is expected to triple, creating enormous burdens on health-care systems, care-givers and communities.
Nymox's AD drug development programs focus on novel proprietary approaches to the diagnosis and treatment of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week